Cauli Cristiana, Barcellona Doris, Marongiu Francesco
Department of Internal Medical Sciences, University of Cagliari, Cagliari, Italy.
Ital Heart J. 2003 Nov;4(11):755-67.
Stroke is the first cause of disability and the second cause of mortality in the world. Oral anticoagulants have been proved to be effective in the primary and secondary prophylaxis of stroke not only in cardiac conditions but also in other pathologies such as the antiphospholipid syndrome. Though the efficacy of oral anticoagulants in the prevention of stroke has been consolidated in several conditions such as mechanical prosthesis, atrial fibrillation, and the antiphospholipid syndrome, their role is less clear in patent foramen ovale, interatrial septal aneurysm, dilated cardiomyopathy, and aortic plaques. Nevertheless, oral anticoagulants have recently been re-evaluated in large clinical trials and have been shown to be effective in the secondary prevention of myocardial infarction and stroke. This review considers both the established and controversial aspects and the role of anticoagulation clinics in the practical approach to these patients, as well as their education and quality of life.
中风是全球致残的首要原因和致死的第二大原因。口服抗凝药已被证明不仅在心脏疾病中，而且在其他病症如抗磷脂综合征中，对中风的一级和二级预防均有效。尽管口服抗凝药在预防中风方面的疗效在诸如机械瓣膜置换、心房颤动和抗磷脂综合征等多种情况下已得到确认，但其在卵圆孔未闭、房间隔瘤、扩张型心肌病和主动脉斑块中的作用尚不清楚。然而，口服抗凝药最近在大型临床试验中得到了重新评估，并已证明在心肌梗死和中风的二级预防中有效。本综述探讨了既定的和有争议的方面，以及抗凝门诊在这些患者实际治疗中的作用，以及患者教育和生活质量。
